Why Semaglutide Causes Constipation and What Helps

Why Does Semaglutide Cause Constipation? It's Several Small Slowdowns, Not One

Constipation on semaglutide doesn't come from one single mechanism working alone. The drug slows the contractions that move food through your stomach and intestines, so digested material lingers longer and your colon pulls out more water, leaving stool harder to pass.¹² That slowdown compounds with something semaglutide does indirectly: eating less, drinking less, and unintentionally cutting fiber during treatment, which is why constipation tends to show up early and stick around.

Several Slowdowns Add Up

There isn't a single "constipation switch" that semaglutide flips. Instead, four things happen at roughly the same time, and each one on its own would be a mild nuisance. Together, they add up to genuinely fewer, harder bowel movements for a real share of users.

The drug slows gut motility directly.¹² You're also eating less, drinking less, and often shifting what you eat, three side effects of appetite suppression that have nothing to do with the drug's mechanism but everything to do with how your colon fills and empties. Here's how each piece plays out, roughly in the order it tends to happen.

Why Semaglutide Slows Your Gut Down in the First Place

Delaying gastric emptying is not an accident of semaglutide, it's one of the mechanisms the drug is built on. The FDA label for Wegovy states plainly that it "delays gastric emptying," which is part of how it helps blunt post-meal blood sugar spikes and prolongs fullness.¹

A 2025 pharmacology review in Endocrinology lays out the biology behind that label line.² Semaglutide taps into a natural feedback loop the authors call the "ileal brake," in which GLP-1 released from cells in your intestine signals your stomach to slow down after eating.² The same review describes a second, separate effect: GLP-1 receptor activation also suppresses the migrating motor complex, the "housekeeping" wave of high-amplitude contractions that normally sweeps leftover food and debris through your small intestine during fasting periods, reducing your gut's ability to clear that material on schedule.²

A small mechanistic trial in women with PCOS and obesity put numbers to this. After 12 weeks of semaglutide 1.0 mg weekly, the rate of measurable food still sitting in the stomach four hours after a test meal rose from about 7% at baseline to 37%, versus 0% in the placebo group (P=.002).³ The median time to empty half a test meal stretched from 118 minutes on placebo to 171 minutes on semaglutide (P<.001), a real but modest difference of under an hour, not the "hours longer" some sources describe.³ This trial excluded people with diabetes or diagnosed gastroparesis and only studied 20 women, so treat it as proof of mechanism rather than a number that applies to everyone.

Why Slower Transit Can Mean Harder, Drier Stool

The general physiology here is well established: the longer stool sits anywhere in your digestive tract, the more time your colon has to reabsorb water from it, and drier stool is harder and more uncomfortable to pass.

A small 2025 case series used wireless motility capsule testing (a swallowed sensor that tracks transit time through the whole gut) in 10 patients already on GLP-1 receptor agonists.⁴ The three patients on the higher semaglutide dose (1 mg) had the longest gastric emptying times in the group and were the only ones with delayed small bowel transit specifically.⁴ This is a retrospective case series with no comparison group and a handful of patients, so it's descriptive evidence, not proof of how often this happens, but it's one of the few places where stomach-to-colon transit has actually been measured start to finish in real semaglutide users.

Direct human evidence that semaglutide itself slows the colon specifically, separate from the well-documented slowing higher up in the stomach and small intestine, is still thin. The same 2025 pharmacology review notes that colonic motility data for GLP-1 drugs remain limited, and in at least one small study, GLP-1 receptor agonist administration actually sped up colonic transit in people with constipation-predominant IBS.² The "slower colon reabsorbs more water" explanation rests more on general GI physiology than on a large, semaglutide-specific dataset measured at the colon itself.

Why Eating and Drinking Less Makes It Worse

Appetite suppression is the point of semaglutide for weight management, but less food volume also means less bulk moving through your colon to trigger the urge to go. A colon that's already working with a smaller load and slower transit has less to push.

Reduced hunger and earlier fullness can also mean people drink less overall, whether because they feel full sooner or because nausea makes fluids less appealing. NIDDK lists both "not eating enough fiber" and "not drinking enough liquids, or dehydration" among the plain, well-established contributors to constipation in general, independent of any medication.⁵ Those risk factors don't stop applying just because the reduced intake is medication-driven instead of voluntary.

Why Your Diet May Have Quietly Shifted, Too

When appetite drops, most people gravitate toward whatever feels tolerable in smaller portions, and that's often simpler, more protein-forward food. Fiber-rich staples like whole grains, beans, and larger produce servings can be the first things to get crowded out of a smaller plate, not because anyone decided to cut fiber, but because it's harder to fit into less food overall.

It's a dietary shift rather than a drug side effect, but it lands directly on top of a gut that's already moving more slowly. NIDDK's own list of constipation contributors includes low fiber intake as one of the most common, regardless of what's causing someone to eat less in the first place.⁵

Why It Often Peaks Around Dose Increases, and Doesn't Always Fully Go Away

Pooled data from the STEP 1-3 trials found constipation in 24.2% of people on semaglutide 2.4 mg, lasting a median of 47 days, compared with 35 days in the placebo group.⁶ Constipation, in other words, ran meaningfully longer than the median duration of nausea (8 days), diarrhea (3 days), or vomiting (2 days) in the same pooled analysis.⁶

Unlike those three symptoms, which tend to peak around week 20 of treatment and then ease off, constipation's prevalence curve plateaus earlier, around week 10, and stays elevated compared with placebo through the full 68-week trial period rather than fading back down to the placebo rate.⁶ For a meaningful share of users, it settles into a new baseline rather than resolving.

One reason it may ease at all over time: a related 2025 review on the clinical consequences of delayed gastric emptying found some evidence of tachyphylaxis with long-acting GLP-1 drugs, meaning the degree of gastric slowing can lessen somewhat with continued use.⁷ That data only extends to about 16 weeks of treatment, though, so what happens with the effect beyond that point isn't established either way.⁷

Dose isn't a simple dial, either. On the Ozempic label (semaglutide's type 2 diabetes formulation), the reported constipation rate at the 1 mg dose (3.1%) was actually lower than at the smaller 0.5 mg dose (5.0%), both above the 1.5% placebo rate.⁸ More milligrams doesn't automatically mean more constipation for everyone, which is part of why the experience varies so much person to person.

When Constipation Is a Red Flag, Not Just a Side Effect

Everyday semaglutide-related constipation is uncomfortable but manageable. A few signs point to something that needs same-day medical attention instead of home remedies: severe or worsening abdominal pain, an inability to pass stool or gas at all, persistent vomiting, or a bloated, rigid abdomen.⁹ These can indicate ileus or a bowel obstruction. FDA postmarketing surveillance for semaglutide-containing products lists ileus, intestinal obstruction, and severe constipation including fecal impaction among reported serious events, alongside acute and necrotizing pancreatitis that has sometimes been fatal.¹

Abdominal pain that radiates to your back, along with fever or persistent nausea and vomiting, can signal pancreatitis. Pain that lasts several hours along with fever, chills, or yellowing of the skin or eyes can signal a gallbladder problem instead. NIDDK's guidance is to seek care right away for either.¹⁰

If you're on semaglutide and constipation is severe, sudden, or paired with any of the above, contact your prescriber or seek care the same day rather than waiting it out. Never stop or adjust a prescribed dose on your own without talking to the clinician who prescribed it.

What Helps While Your Gut Is Working Against You

Fiber is the most-studied lever here, though not from semaglutide-specific trials. A 2022 systematic review and meta-analysis of fiber supplementation for chronic constipation in the general population found a sensitivity-analysis increase of about 1.19 bowel movements per week, with psyllium specifically showing a larger increase of about 3.08 per week.¹¹ The same review found fiber significantly worsened flatulence but didn't change bloating scores, a real trade-off worth planning around rather than a reason to avoid fiber altogether.¹¹

Fluids and movement matter for the same physiological reasons constipation happens in the first place: more water keeps stool softer, and physical activity supports the colon's own contractions. Neither is glamorous, but both address root causes rather than just easing symptoms.

Magnesium oxide is a reasonable short-term, over-the-counter option many people reach for, per NIH and consumer drug information, though the same guidance is explicit that it shouldn't be used as a laxative for longer than a week without a doctor's advice, and people with kidney disease should check with a clinician before using it regularly.¹²

Gut microbiome support is a newer, still-developing part of this picture, and it's the one we built around most deliberately. HN019, a probiotic strain studied specifically for constipation rather than gut health in general, has shown a modest transit-time benefit in a targeted subgroup in one trial and a significant reduction in abdominal pain and bloating scores as a secondary result in a larger, more recent 229-person trial^13,14, a real, if not always primary-endpoint-clearing, signal across the research base behind this strain. None of that research has tested people taking semaglutide specifically, which is worth knowing going in.

That research is part of why we built WonderBiotics Daily Fiber Mix the way we did. Since a slower gut is already prone to gas and bloating, a single fixed fiber dose didn't make sense as the only option: it blends five fiber types, including gentler, slower-fermenting fibers alongside faster-fermenting ones like FOS, in adjustable 6 g sachets you can dose from one to three per day. That lets you find the amount your gut actually tolerates instead of guessing at a one-size-fits-all scoop, which matters more, not less, when transit is already running slow.

For the daily microbiome side of the equation, our WonderBiotics Probiotics for Gut Health formula pairs HN019 with 11 other studied strains at 60 billion CFU, a routine habit that works alongside the fluid and fiber basics above, backed by the most direct human evidence we could find for a strain in this category.

When to Call Your Doctor

Semaglutide-related constipation is common enough to expect, especially in the weeks right after a dose increase, but it's not something to just push through indefinitely. Bring it up at your next visit if it's persistent, and call the same day for severe pain, an inability to pass stool or gas, or any of the red flags above. Your prescriber can also check whether other medications, a slower dose titration, or a short course of an over-the-counter option makes sense for your specific situation.

References

1. Wegovy (semaglutide) Prescribing Information, DailyMed
2. Jalleh RJ, Marathe CS, Rayner CK, et al. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. 2025;166(1):bqae155.
3. Jensterle M, et al. Semaglutide delays 4-hour gastric emptying in women with PCOS and obesity. Diabetes Obes Metab. 2023;25(4):975-984. PMID 36511825.
4. Cymbal M, Naseem Z, Hoxha D, Garg S. Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series. ACG Case Rep J. 2025;12(8):e01789. PMID 40761333.
5. NIDDK. Symptoms & Causes of Constipation.
6. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. PMID 34514682.
7. Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2025;110(1):1-15.
8. Ozempic (semaglutide) Prescribing Information, DailyMed
9. MedlinePlus. Intestinal Obstruction.
10. NIDDK. Symptoms & Causes of Pancreatitis and NIDDK. Symptoms & Causes of Gallstones
11. van der Schoot A, Drysdale C, Whelan K, Dimidi E. The effect of fiber supplementation on chronic constipation in adults: an updated systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2022;116(4):953-969.
12. NIH Office of Dietary Supplements. Magnesium - Health Professional Fact Sheet and MedlinePlus. Magnesium Oxide (Oral Route)
13. Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. 2018;9(3):236-251. PMID 29227175.
14. Cheng J, Gao C, Ala-Jaakkola R, et al. Eight-Week Supplementation With Bifidobacterium lactis HN019 and Functional Constipation: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(10):e2436888. PMID 39356506.